The 4 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +54.80% increase from the last price of 3.23.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.07
Reporting Date Mar 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.